PGNY Stock Price, Progyny Inc Quote, Chart

Market Summary

USD32.90+0.20

Delayedas of 22 Apr 2024, 12:05 pm

0.61%

PGNY Alerts

3 major insider sales recently.

PGNY Stock Price

View Fullscreen

PGNY RSI Chart

PGNY Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

50.87

Price/Sales (Trailing)

2.9

EV/EBITDA

40.09

Price/Free Cashflow

17.04

PGNY Price/Sales (Trailing)

PGNY Profitability

EBT Margin

6.49%

Return on Equity

11.21%

Return on Assets

8.2%

Free Cashflow Yield

5.87%

PGNY Fundamentals

PGNY Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

25.95%

Rev. Growth (Qtr)

-3.9%

PGNY Earnings

Earnings (TTM)

62.0M

Earnings Growth (Yr)

295.25%

Earnings Growth (Qtr)

-15.27%

Breaking Down PGNY Revenue

52 Week Range

32.0944.95

(Low)(High)

Last 7 days

-4.4%

Last 30 days

-10.6%

Last 90 days

-12.6%

Trailing 12 Months

-4.5%

How does PGNY drawdown profile look like?

PGNY Financial Health

Current Ratio

3.44

PGNY Investor Care

Shares Dilution (1Y)

3.34%

Diluted EPS (TTM)

0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	873.1M	957.5M	1.0B	1.1B
2022	550.7M	617.1M	700.1M	786.9M
2021	386.0M	450.0M	473.4M	500.6M
2020	263.5M	271.9M	309.7M	344.9M
2019	130.3M	160.3M	193.7M	229.7M
2018	62.8M	77.0M	91.2M	105.4M
2017	0	0	0	48.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Progyny Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 23, 2024	payson norman	sold	-11,258	56.29	-200	-
Apr 01, 2024	livingston mark s.	acquired	81,476	3.95	20,627	chief financial officer
Apr 01, 2024	livingston mark s.	sold (taxes)	-436,320	37.643	-11,591	chief financial officer
Apr 01, 2024	livingston mark s.	sold	-419,979	37.6157	-11,165	chief financial officer
Apr 01, 2024	schlanger david j	sold (taxes)	-102,280	38.15	-2,681	executive chairman
Apr 01, 2024	anevski peter	sold (taxes)	-304,323	38.15	-7,977	chief executive officer
Apr 01, 2024	schlanger david j	acquired	3,950	3.95	1,000	executive chairman
Apr 01, 2024	sturmer michael e	sold	-240,452	37.6	-6,395	president
Apr 01, 2024	schlanger david j	sold	-37,522	37.5225	-1,000	executive chairman
Mar 27, 2024	schlanger david j	sold	-2,694,270	37.8026	-71,272	executive chairman

Which funds bought or sold PGNY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	DEEPWATER ASSET MANAGEMENT, LLC	added	24.06	3,216,670	14,998,700	5.65%
Apr 18, 2024	Park Place Capital Corp	added	23.58	10,566	49,977	0.02%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	9.5	26,261	238,819	-%
Apr 18, 2024	Congress Wealth Management LLC / DE /	added	27.42	1,348,360	5,734,670	0.10%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-21,341	-	-%
Apr 18, 2024	STATE OF MICHIGAN RETIREMENT SYSTEM	added	2.5	38,455	781,274	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	24.00	954	-%
Apr 17, 2024	ATTICUS WEALTH MANAGEMENT, LLC	unchanged	-	60.00	2,328	-%
Apr 17, 2024	NEW MEXICO EDUCATIONAL RETIREMENT BOARD	reduced	-7.79	157,000	730,000	0.03%
Apr 16, 2024	Financial Management Professionals, Inc.	new	-	52,000	52,000	0.01%

Are Funds Buying or Selling PGNY?

Are funds buying PGNY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PGNY

No. of Funds

PGNY Alerts

3 major insider sales recently.

Unveiling Progyny Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	kleiner perkins caufield & byers xiii, llc	5.3%	5,074,615	SC 13G/A
Feb 14, 2024	macquarie group ltd	1.54%	1,481,588	SC 13G/A
Feb 13, 2024	tpg gp a, llc	7.2%	6,903,267	SC 13G/A
Feb 13, 2024	vanguard group inc	8.63%	8,270,153	SC 13G/A
Jan 23, 2024	blackrock inc.	12.6%	12,111,570	SC 13G/A
Feb 14, 2023	macquarie group ltd	5.37%	4,988,789	SC 13G/A
Feb 14, 2023	alger associates inc	2.6%	2,372,711	SC 13G/A
Feb 10, 2023	tpg gp a, llc	10.5%	9,815,351	SC 13G/A
Feb 09, 2023	vanguard group inc	7.91%	7,345,124	SC 13G/A
Jan 06, 2023	blackrock inc.	10.1%	9,346,854	SC 13G/A

Recent SEC filings of Progyny Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Progyny Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	461.9B	371.6B	1.38%	2.78%	20.64	1.24	14.64%	11.24%
CI	103.1B	195.3B	-0.38%	37.81%	19.18	0.53	8.17%	-20.79%
CVS	87.8B	357.8B	-11.69%	-4.78%	10.51	0.25	10.95%	93.52%
HCA	80.7B	65.0B	-7.20%	12.71%	15.4	1.24	7.86%	-7.11%
CNC	40.2B	154.0B	-3.58%	14.01%	14.86	0.26	6.54%	124.79%
DVA	11.2B	12.1B	-7.92%	53.74%	16.21	0.92	4.57%	23.40%
UHS	10.9B	14.3B	-12.49%	15.68%	15.2	0.76	6.59%	6.24%
MID-CAP
CHE	9.1B	2.3B	-6.50%	6.12%	33.31	4.01	6.06%	9.17%
ACHC	6.5B	2.9B	-8.97%	-3.82%	-298.84	2.21	12.20%	-107.93%
AMN	2.2B	3.8B	-13.83%	-35.23%	10.24	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-10.13%	1.91%	34.08	1.49	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-3.82%	-13.66%	25.23	1.49	11.31%	35.83%
BKD	1.2B	3.0B	1.73%	53.19%	-6.49	0.41	6.74%	20.73%
BEAT	50.8M	-	-10.91%	-11.71%	-3.47	-	-	-12.94%
AMS	18.9M	21.3M	12.41%	5.40%	35.51	0.89	8.00%	-62.25%

Progyny Inc News

Latest updates

Progyny Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-3.9%	270	281	279	258	214	205	195	172	128	122	129	122	100	99.00	65.00	81.00	65.00	61.00	56.00	47.00	29.00
Gross Profit	-9.1%	57.00	63.00	61.00	59.00	44.00	46.00	44.00	33.00	25.00	28.00	30.00	29.00	21.00	21.00	12.00	17.00	12.00	12.00	11.00	10.00	5.00
Operating Expenses	-3.0%	43.00	44.00	45.00	44.00	41.00	35.00	35.00	33.00	25.00	19.00	18.00	17.00	20.00	16.00	13.00	13.00	11.00	9.00	9.00	7.00	6.00
S&GA Expenses	0%	15.00	15.00	15.00	14.00	13.00	11.00	11.00	10.00	8.00	4.00	4.00	4.00	5.00	3.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00
EBITDA Margin	13.5%	0.07*	0.06*	0.06*	0.05*	0.03*	0.03*	0.03*	0.04*	0.07*	0.08*	0.07*	0.05*	-	-	-	-	-	-	-	-	-
Interest Expenses	-28.2%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02	-0.02	-0.02	0.00	0.00	0.00	-0.03	-0.13	-0.04	-0.04
Income Taxes	-44.5%	3.00	5.00	2.00	-1.35	1.00	-1.67	0.00	-5.11	-15.48	-7.68	-6.81	-3.37	-37.90	0.00	-0.02	0.00	-0.08	0.00	0.00	-	-0.55
Earnings Before Taxes	-22.3%	16.00	21.00	17.00	16.00	4.00	12.00	9.00	-0.14	-0.40	9.00	12.00	12.00	1.00	5.00	-1.06	4.00	-4.48	-8.18	2.00	3.00	-2.12
EBT Margin	14.5%	0.06*	0.06*	0.05*	0.05*	0.03*	0.03*	0.03*	0.04*	0.06*	0.07*	0.07*	0.04*	-	-	-	-	-	-	-	-	-
Net Income	-15.3%	13.00	16.00	15.00	18.00	3.00	13.00	9.00	5.00	15.00	17.00	19.00	15.00	39.00	5.00	-1.06	4.00	-4.40	-8.21	2.00	3.00	-1.52
Net Income Margin	13.3%	0.06*	0.05*	0.05*	0.05*	0.04*	0.06*	0.07*	0.10*	0.13*	0.19*	0.17*	0.15*	-	-	-	-	-	-	-	-	-
Free Cashflow	-30.5%	37.00	53.00	75.00	20.00	51.00	20.00	19.00	-12.05	8.00	23.00	-7.90	0.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	4.1%	757	727	682	650	543	510	463	416	358	337	312	295	254	202	178	180	150	73.00	41.00
Current Assets	4.8%	640	611	561	527	434	402	356	309	259	254	238	228	190	185	160	162	132	53.00	25.00
Cash Equivalents	-38.4%	97.00	158	171	155	120	73.00	55.00	39.00	91.00	92.00	49.00	30.00	70.00	54.00	49.00	92.00	80.00	8.00	0.00
Net PPE	5.1%	10.00	10.00	9.00	9.00	8.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00	3.00	4.00	4.00	4.00	3.00	1.00	1.00
Goodwill	0%	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Liabilities	-3.8%	203	211	212	225	166	164	152	136	106	113	108	110	87.00	75.00	58.00	59.00	36.00	58.00	30.00
Current Liabilities	-3.9%	186	193	194	207	160	157	145	129	99.00	104	99.00	101	78.00	74.00	58.00	59.00	36.00	58.00	30.00
Shareholder's Equity	7.4%	553	515	469	424	377	347	311	280	252	224	205	185	167	126	119	119	114	-	-
Retained Earnings	17.6%	90.00	77.00	61.00	46.00	28.00	25.00	11.00	3.00	-2.42	-17.50	-34.30	-53.03	-68.19	-105	-111	-109	-113	-109	-104
Additional Paid-In Capital	5.4%	462	438	409	379	350	323	301	278	255	243	240	239	236	234	232	232	229	19.00	11.00
Shares Outstanding	0.9%	96.00	96.00	95.00	94.00	93.00	92.00	92.00	91.00	89.00	90.00	88.00	87.00	-	-	-	-	-	-	-
Float	-	-	-	3,300	-	-	-	2,300	-	-	-	4,100	-	-	-	1,100	-	1,100	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-30.5%	37,659	54,182	76,012	20,961	51,517	20,894	19,246	-11,262	8,815	24,163	-7,473	532	6,537	15,329	2,197	12,140	-5,489	5,879	4,247	-6,171	-
Share Based Compensation	-7.8%	28,799	31,251	31,753	30,808	29,297	23,297	23,654	24,500	15,008	7,147	6,517	5,034	4,160	3,071	3,541	2,049	1,852	1,680	1,012	517	-
Cashflow From Investing	-45.2%	-93,414	-64,315	-58,923	16,127	-1,173	-1,876	-1,259	-39,558	-6,312	22,374	31,224	-38,520	11,887	-9,148	-42,077	-693	-2,278	-420	-133	75.00	-
Cashflow From Financing	-112.7%	-5,025	-2,362	-1,839	-1,846	-2,786	-1,228	-2,078	-1,772	-3,314	-3,060	-4,824	-2,497	-2,084	-1,608	-2,363	-194	80,485	1,907	-4,180	6,333	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	-	-	-	-

PGNY Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 269,940	$ 280,891	$ 279,373	$ 258,394	$ 214,321	$ 205,371	$ 195,004	$ 172,217	$ 1,088,598	$ 786,913	$ 500,621
Cost of services	213,046	218,267	218,732	199,754	169,827	159,376	151,117	139,268	849,799	619,588	388,486
Gross profit	56,894	62,624	60,641	58,640	44,494	45,995	43,887	32,949	238,799	167,325	112,135
Operating expenses:
Sales and marketing	14,911	14,911	15,384	14,282	12,980	11,166	11,496	10,015	59,488	45,657	20,179
General and administrative	28,183	29,524	30,073	29,347	28,208	23,574	23,553	22,992	117,127	98,327	59,616
Total operating expenses	43,094	44,435	45,457	43,629	41,188	34,740	35,049	33,007	176,615	143,984	79,795
Income from operations	13,800	18,189	15,184	15,011	3,306	11,255	8,838	(58)	62,184	23,341	32,340
Other income, net:
Other income (expense), net	1,720	1,708	1,277	498	275	82	25	(96)	5,203	286	(366)
Interest income, net	742	1,034	706	822	560	202	40	12	3,304	814	461
Total other income (expense), net	2,462	2,742	1,983	1,320	835	284	65	(84)	8,507	1,100	95
Income (loss) before income taxes	16,262	20,931	17,167	16,331	4,141	11,539	8,903	(142)	70,691	24,441	32,435
Provision (benefit) for income taxes	2,792	5,033	2,176	(1,347)	733	(1,672)	135	(5,113)	8,654	(5,917)	(33,334)
Net income	$ 13,470	$ 15,898	$ 14,991	$ 17,678	$ 3,408	$ 13,211	$ 8,768	$ 4,971	$ 62,037	$ 30,358	$ 65,769
Net income per share:
Basic (in dollars per share)	$ 0.14	$ 0.17	$ 0.16	$ 0.19	$ 0.04	$ 0.14	$ 0.10	$ 0.05	$ 0.65	$ 0.33	$ 0.74
Diluted (in dollars per share)	$ 0.13	$ 0.16	$ 0.15	$ 0.18	$ 0.03	$ 0.13	$ 0.09	$ 0.05	$ 0.62	$ 0.30	$ 0.66
Weighted-average shares used in computing net income per share:
Basic (in shares)	95,980,425	95,502,250	94,738,651	93,832,873	93,056,297	92,316,022	91,964,978	91,410,368	95,021,175	92,195,068	89,105,562
Diluted (in shares)	100,748,054	100,879,576	100,615,919	100,166,008	100,059,687	99,819,801	99,672,769	99,935,735	100,672,399	99,957,173	100,358,047

PGNY Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 97,296	$ 120,078
Marketable securities	273,791	69,222
Accounts receivable, net of $46,636 and $28,328 of allowances at December 31, 2023 and 2022, respectively	241,869	240,067
Prepaid expenses and other current assets	27,451	4,489
Total current assets	640,407	433,856
Property and equipment, net	10,213	8,371
Operating lease right-of-use assets	17,605	6,903
Goodwill	11,880	11,880
Intangible assets, net	0	99
Deferred tax assets	73,120	77,889
Other noncurrent assets	3,395	3,988
Total assets	756,620	542,986
Current liabilities:
Accounts payable	125,426	109,287
Accrued expenses and other current liabilities	60,524	50,249
Total current liabilities	185,950	159,536
Operating lease noncurrent liabilities	17,241	6,482
Total liabilities	203,191	166,018
Commitments and Contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.0001 par value; 1,000,000,000 shares authorized at December 31, 2023 and 2022, respectively; 96,348,522 and 93,301,156 shares issued and outstanding at December 31, 2023 and 2022, respectively	9	9
Additional paid-in capital	461,639	349,533
Treasury stock, at cost, $0.0001 par value; 615,980 shares outstanding at December 31, 2023 and 2022, respectively	(1,009)	(1,009)
Accumulated earnings	89,971	27,934
Accumulated other comprehensive income	2,819	501
Total stockholders’ equity	553,429	376,968
Total liabilities and stockholders’ equity	$ 756,620	$ 542,986

About Progyny Inc

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

CEO	Mr. Peter Anevski
WEBSITE	progyny.com
INDUSTRY	Healthcare Plans
EMPLOYEES	393

Progyny Inc Frequently Asked Questions

What is the ticker symbol for Progyny Inc? What does PGNY stand for in stocks?

PGNY is the stock ticker symbol of Progyny Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Progyny Inc (PGNY)?

As of Fri Apr 19 2024, market cap of Progyny Inc is 3.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PGNY stock?

You can check PGNY's fair value in chart for subscribers.

What is the fair value of PGNY stock?

You can check PGNY's fair value in chart for subscribers. The fair value of Progyny Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Progyny Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PGNY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Progyny Inc a good stock to buy?

The fair value guage provides a quick view whether PGNY is over valued or under valued. Whether Progyny Inc is cheap or expensive depends on the assumptions which impact Progyny Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGNY.

What is Progyny Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, PGNY's PE ratio (Price to Earnings) is 50.87 and Price to Sales (PS) ratio is 2.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGNY PE ratio will change depending on the future growth rate expectations of investors.